Pulse Biosciences, Inc (PLSE): Price and Financial Metrics
PLSE Price/Volume Stats
| Current price | $16.10 | 52-week high | $22.69 |
| Prev. close | $16.53 | 52-week low | $3.78 |
| Day low | $15.90 | Volume | 106,900 |
| Day high | $16.75 | Avg. volume | 209,778 |
| 50-day MA | $17.49 | Dividend yield | N/A |
| 200-day MA | $12.02 | Market Cap | 889.12M |
PLSE Stock Price Chart Interactive Chart >
Pulse Biosciences, Inc (PLSE) Company Bio
Pulse Biosciences, a development stage medical device company, focuses on developing medical technologies based on sub-microsecond pulsed electric field technology to detect and treat skin cancer and enhance wound healing. The company was founded in 2014 and is based in Burlingame, California.
Latest PLSE News From Around the Web
Below are the latest news stories about PULSE BIOSCIENCES INC that investors may wish to consider to help them evaluate PLSE as an investment opportunity.
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac CatheterHAYWARD, Calif., December 20, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the completion of the first five procedures in its first-in-human feasibility study with its novel CellFX nsPFA cardiac catheter. All patients were successfully discharged by treating physicians. Patients will continue to be monitored and |
Executive Chairman of Pulse Biosciences Robert Duggan Buys More StockPulse Biosciences, Inc. ( NASDAQ:PLSE ) shareholders (or potential shareholders) will be happy to see that the... |
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous ElectrodeHAYWARD, Calif., November 21, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced the filing of a premarket notification 510(k) to the U.S. Food and Drug Administration (FDA) for its novel CellFX nsPFA percutaneous electrode. |
Chief Strategy Officer of Pulse Biosciences Picks Up 24% More StockInvestors who take an interest in Pulse Biosciences, Inc. ( NASDAQ:PLSE ) should definitely note that the Chief... |
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare ConferenceHAYWARD, Calif., November 15, 2023--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced plans to present at the upcoming 35th Annual Piper Sandler Healthcare Conference in New York. |
PLSE Price Returns
| 1-mo | -4.90% |
| 3-mo | 33.61% |
| 6-mo | 112.68% |
| 1-year | 287.02% |
| 3-year | -21.46% |
| 5-year | 10.58% |
| YTD | 31.54% |
| 2023 | 341.88% |
| 2022 | -81.30% |
| 2021 | -37.93% |
| 2020 | 77.93% |
| 2019 | 17.02% |
Loading social stream, please wait...